SEC Comment Letter 0000000000-23-007069 to Trevi Therapeutics, Inc. (TRVI) (CIK 0001563880) (TRVI)
Trevi Therapeutics, Inc. (TRVI) (CIK 0001563880)
Date: July 5, 2023 · CIK: 0001563880 · Accession: 0000000000-23-007069
AI Filing Summary & Sentiment
File numbers found in text: 333-273030
Letter
United States securities and exchange commission logo July 5, 2023 Jennifer Good President and Chief Executive Officer Trevi Therapeutics, Inc. 195 Church Street, 16th Floor New Haven, Connecticut 06510 Re:Trevi Therapeutics, Inc. Registration Statement on Form S-3 Filed June 29, 2023 File No. 333-273030 Dear Jennifer Good: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dillon Hagius at 202-551-7967 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Stuart Falber
Show Raw Text
United States securities and exchange commission logo
July 5, 2023
Jennifer Good
President and Chief Executive Officer
Trevi Therapeutics, Inc.
195 Church Street, 16th Floor
New Haven, Connecticut 06510
Re:Trevi Therapeutics, Inc.
Registration Statement on Form S-3
Filed June 29, 2023
File No. 333-273030
Dear Jennifer Good:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Dillon Hagius at 202-551-7967 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Stuart Falber